Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis: A Dose-Ranging Study

  title={Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis: A Dose-Ranging Study},
  author={Steven E. Chavoustie and M. J. Jacobs and Howard A. Reisman and Arthur S. Waldbaum and Sharon F. Levy and Sharon Louise Hillier and Paul Nyirjesy},
  booktitle={Journal of lower genital tract disease},
OBJECTIVE Metronidazole vaginal gel (MVG) 0.75% is a US Food and Drug Administration-approved, 5-day treatment for bacterial vaginosis (BV). This study tested the hypothesis that a shorter treatment course at a higher dose (MVG 1.3%) would yield similar efficacy to 5 days of MVG 0.75%. MATERIALS AND METHODS This phase 2, multicenter, randomized, controlled, investigator-blinded, dose-ranging study enrolled women with a clinical diagnosis of BV. Patients were assigned to MVG 1.3% once daily… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 8 times. VIEW TWEETS


Publications referenced by this paper.
Showing 1-10 of 13 references

Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomised controlled trial.Obstet Gynecol 2007;110 (2 Pt 1):302–9

CH IIILivengood, DG Ferris, +3 authors P Nyirjesy

The vaginal microbiome: new information about genital tract flora using molecular based techniques.

BJOG : an international journal of obstetrics and gynaecology • 2011
View 2 Excerpts

Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2008

Sexually transmitted diseases treatment guidelines, 2006.

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports • 2006

Similar Papers

Loading similar papers…